These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Mutations of the BRAF gene in benign and malignant melanocytic lesions. Yazdi AS; Palmedo G; Flaig MJ; Puchta U; Reckwerth A; Rütten A; Mentzel T; Hügel H; Hantschke M; Schmid-Wendtner MH; Kutzner H; Sander CA J Invest Dermatol; 2003 Nov; 121(5):1160-2. PubMed ID: 14708620 [TBL] [Abstract][Full Text] [Related]
3. BRAF and NRAS mutations in melanoma and melanocytic nevi. Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322 [TBL] [Abstract][Full Text] [Related]
4. BRAF mutations are common somatic events in melanocytic nevi. Kumar R; Angelini S; Snellman E; Hemminki K J Invest Dermatol; 2004 Feb; 122(2):342-8. PubMed ID: 15009715 [TBL] [Abstract][Full Text] [Related]
5. BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Uribe P; Wistuba II; González S Am J Dermatopathol; 2003 Oct; 25(5):365-70. PubMed ID: 14501284 [TBL] [Abstract][Full Text] [Related]
6. BRAF point mutations in primary melanoma show different prevalences by subtype. Sasaki Y; Niu C; Makino R; Kudo C; Sun C; Watanabe H; Matsunaga J; Takahashi K; Tagami H; Aiba S; Horii A J Invest Dermatol; 2004 Jul; 123(1):177-83. PubMed ID: 15191558 [TBL] [Abstract][Full Text] [Related]
7. SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant. Tsavachidou D; Coleman ML; Athanasiadis G; Li S; Licht JD; Olson MF; Weber BL Cancer Res; 2004 Aug; 64(16):5556-9. PubMed ID: 15313890 [TBL] [Abstract][Full Text] [Related]
8. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Hingorani SR; Jacobetz MA; Robertson GP; Herlyn M; Tuveson DA Cancer Res; 2003 Sep; 63(17):5198-202. PubMed ID: 14500344 [TBL] [Abstract][Full Text] [Related]
9. Impact of oncogenic BRAF mutations and p16 expression on the growth rate of early melanomas and naevi in vivo. Tschandl P; Berghoff AS; Preusser M; Pammer J; Pehamberger H; Kittler H Br J Dermatol; 2016 Feb; 174(2):364-70. PubMed ID: 26613644 [TBL] [Abstract][Full Text] [Related]
10. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis. Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298 [TBL] [Abstract][Full Text] [Related]
11. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Dong J; Phelps RG; Qiao R; Yao S; Benard O; Ronai Z; Aaronson SA Cancer Res; 2003 Jul; 63(14):3883-5. PubMed ID: 12873977 [TBL] [Abstract][Full Text] [Related]